ReviewThe oncologist2020

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

Samuel J Klempner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.